Laura Ferris, M.D., Ph.D.
DERMATOLOGY
Laura Ferris, MD, PhD, joined the Department of Dermatology in 2006, after completing her Dermatology Residency and Investigative Dermatology Fellowship at the University of Pittsburgh. Dr. Ferris earned her undergraduate degree in biology, from Marquette University; she completed her PhD in Immunology at Johns Hopkins Medical School, and received her medical degree from the University of Maryland. Dr. Ferris practices general medical dermatology with a special focus on skin cancer and psoriasis. She also directs the Clinical Trials Unit in the Department of Dermatology and has served as a principal investigator on more than 30 clinical trials in Dermatology, primarily in the area of new treatments for psoriasis. She has been an invited speaker at several national and international meetings and has published more than 60 book chapters and articles in the peer-reviewed literature.
See More Experts
Dr. Doughlas
Grossman
Dermatology
Dr. Jerad Gardner
Dermatopathology
Dr. Sancy Leachman
Dermatology
12/2022
Interview with Dr. Laura Ferris, MD
JUMP TO SECTION
01
(0:05 - 1:08)
Introduction
02
(1:08 - 5:42)
How does Dr. Ferris take care of patient with high-risk melanoma? Who are at high risk? The use of dermoscopy, skin check, and mole mapping. Efforts to avoid unnecessary biopsies. Importance of trust between physcians and patients.
03
(5:42 - 7:37)
Do I need to take off my undergarments?
04
(7:37 - 11:24)
What is Genetic Expression Profiling (GEP)? Examining RNA of the tumor. Difficulty in diagnosing melanoma.
05
(11:25 - 23:36)
Use GEP technology to diagnose melanoma with the Dermtech with PLA assay. Use non-invasive tape to extract RNA and DNA from a skin lesion. Stability of genetic materials. How long does it take to get the results back? How accurate is the test? What is the best clinical scenario to use this test? Can it be used on kids?
06
(23:35 - 31:47)
Skin cancer prevention program can help detect melanoma early? How do you teach primary care physician to recognize melanoma? Can we train our patients to recognize melanoma using the same approach? How to recognize benign vs. malignant lesions? Use of AI and tele-dermatolgoy to triage patients
07
(31:48 - 32:27)
Conclusion.